Intervacc Future Growth

Future criteria checks 2/6

Intervacc is forecast to grow earnings and revenue by 33.2% and 88.3% per annum respectively while EPS is expected to grow by 32.8% per annum.

Key information

33.2%

Earnings growth rate

32.8%

EPS growth rate

Biotechs earnings growth36.4%
Revenue growth rate88.3%
Future return on equityn/a
Analyst coverage

Low

Last updated30 Aug 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:2E9 - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026113-38-35-321
12/31/202545-62-58-561
12/31/202417-69-62-611
6/30/202410-103-50-49N/A
3/31/20249-103-54-52N/A
12/31/20238-103-48-46N/A
9/30/202310-106-57-55N/A
6/30/202310-73-60-57N/A
3/31/202312-71-65-62N/A
12/31/202212-64-76-70N/A
9/30/202210-50-70-57N/A
6/30/202210-44-65-47N/A
3/31/20229-34-55-33N/A
12/31/20219-29-49-25N/A
9/30/20219-28-43-24N/A
6/30/20218-26-38-22N/A
3/31/20217-26-36-23N/A
12/31/20207-26-31-20N/A
9/30/20207-26-35-18N/A
6/30/20208-26-39-15N/A
3/31/20209-29-45-10N/A
12/31/201914-28-42-3N/A
9/30/201916-27-400N/A
6/30/201926-26-296N/A
3/31/201941-29-280N/A
12/31/201838-27-28-4N/A
9/30/201838-27-32-12N/A
6/30/201838-24-36-17N/A
3/31/201843-16N/A-28N/A
12/31/201750-13N/A-19N/A
9/30/201752-11N/A-17N/A
6/30/201756-9N/A-23N/A
3/31/201763-6N/A-1N/A
12/31/201658-7N/A-4N/A
12/31/2015650N/A-19N/A
12/31/2014809N/AN/AN/A
12/31/20131-2N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2E9 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 2E9 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 2E9 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 2E9's revenue (88.3% per year) is forecast to grow faster than the German market (5.5% per year).

High Growth Revenue: 2E9's revenue (88.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 2E9's Return on Equity is forecast to be high in 3 years time


Discover growth companies